Susquehanna International Group’s Sonnet BioTherapeutics SONN Stock Holding History

Susquehanna International Group’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,307	Closed	-$64.1K	–	13161
2024 Q1	$64.1K	Buy	+4,307	New	+$57.8K	﹤0.01%	11452
2023 Q3	–	Sell	-100	Closed	-$8.6K	–	12908
2023 Q2	$8.6K	Buy	+100	New	+$7.05K	﹤0.01%	11776
2022 Q3	–	Sell	-43	Closed	-$30K	–	14060
2022 Q2	$30K	Sell	43 -40	-48%	-$28.7K	﹤0.01%	12225
2022 Q1	$77K	Buy	+83	New	+$70.2K	﹤0.01%	12075
2021 Q1	–	Sell	-6	Closed	-$34K	–	12811
2020 Q4	$34K	Buy	+6	New	+$38.1K	﹤0.01%	10823
2020 Q2	–	Hold	0	–	-$7K	–	10859
2020 Q1	–	Hold	0	–	–	–	10077
2019 Q1	–	Hold	0	–	-$19K	–	9777
2018 Q4	–	Hold	0	–	–	–	8687
2018 Q1	–	Hold	0	–	-$37K	–	10121
2017 Q4	–	Hold	0	–	–	–	8985
2016 Q1	–	Hold	0	–	-$24K	–	9626
2015 Q4	–	Hold	0	–	–	–	9205
2015 Q3	–	Hold	0	–	–	–	9272
2015 Q2	–	Hold	0	–	–	–	9912
2015 Q1	–	Hold	0	–	–	–	8233

Other funds holding SONN

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group's SONN Position: Q2 2024 in Review

Susquehanna International Group sold out of Sonnet BioTherapeutics (SONN) in Q2 2024, closing a stake of 4,307 shares — an estimated $64.1K sold.

Susquehanna International Group first reported a position in SONN in Q4 2020 and held it in 5 quarters. The position peaked at $77K in Q1 2022. 10 funds tracked by Wall St. Rank hold SONN as of Q2 2024.

Susquehanna International Group reported no remaining Sonnet BioTherapeutics position as of Q2 2024 after selling out during the quarter.
Susquehanna International Group sold 4,307 Sonnet BioTherapeutics shares in Q2 2024, an estimated $64.1K.
Susquehanna International Group first reported a position in Sonnet BioTherapeutics in Q4 2020 and held it in 5 quarters.
Susquehanna International Group's Sonnet BioTherapeutics position peaked at $77K in Q1 2022.
10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.